Sulfonamide compounds having TRPM8 antagonistic activity

A method for treating a disease or condition selected from chronic pain, cephalalgia, urologic disease, carcinoma, respiratory disease, gastrointestinal disease, psychiatric disease, neurological disease, and dermatosis, the method comprising administering to a subject an effective amount of a compound of the following formula:

• is bicyclic aromatic heterocycle comprised of pyridine condensed with benzene,
• one of Y and Z is CR2d, and the other is a chemical bond
• Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon;
• (b) monocyclic or bicyclic alicyclic hydrocarbon;
• (c) monocyclic or bicyclic aromatic heterocycle;
• or (d) monocyclic or bicyclic non-aromatic heterocycle,
• Ring C is (a) benzene;
• or (b) monocyclic aromatic heterocycle,
• R1 is (a) hydrogen;
• (b) optionally substituted alkyl;
• (c) optionally substituted cycloalkyl;
• (d) optionally substituted alkoxy;
• (e) optionally substituted phenyl;
• (f) halogen;
• or (g) nitrile,
• R2a, R2b, R2c and R2d are each independently (a) hydrogen;
• (b) optionally substituted alkyl;
• (c) optionally substituted cycloalkyl;
• (d) optionally substituted alkoxy;
• (e) optionally substituted phenyl;
• (f) optionally substituted monocyclic aromatic heterocyclic group;
• (g) optionally substituted monocyclic non-aromatic heterocyclic group;
• (h) halogen;
• or (i) nitrile,
• R3a, R3b, R3c and R3d are each independently (a) hydrogen;
• (b) optionally substituted alkyl;
• (c) optionally substituted cycloalkyl;
• (d) optionally substituted alkoxy;
• (e) optionally substituted cycloalkoxy;
• (f) optionally substituted phenyl;
• (g) optionally substituted monocyclic aromatic heterocyclic group;
• (h) optionally substituted monocyclic non-aromatic heterocyclic group;
• (i) optionally substituted phenoxy;
• (j) halogen;
• or (k) hydroxy, or
• two substituent groups selected from R3a, R3b, R3c and R3d combine each other to form oxo,
• R5 and R6 are each independently (a) hydrogen;
• (b) alkyl;
• (c) halogenoalkyl;
• (d) cycloalkyl;
• or (e) halogenocycloalkyl, or R5 and R6 combine each other at their terminals together with the adjacent carbon atom to form monocyclic alicyclic hydrocarbon,
• n is 0, 1 or 2,
• X is carboxy, alkoxycarbonyl, hydroxyalkyl, optionally substituted aminocarbonyl, or optionally substituted alkanoyl;
• or a pharmaceutically acceptable salt thereof.